The Canadian vantage point

Companies based outside the U.S. get a different view of the institutional investment scene, in some ways broader and in others more constrained.

BioChem Pharma Inc. isn't well known in the U.S. for a number of reasons, despite the fact that at close to $500 million, it has one of the highest market caps in the industry and is about to become profitable. Its portfolio of marketed diagnostic and vaccine products is backed by a pipeline that includes late-stage